Novo Nordisk in short
Novo Nordisk sales totalled DKK 83.572 million (EUR 11.202 million) in 2013. With headquarters in Denmark, Novo Nordisk employs approximately 38.000 full-time employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
Triple bottom line focus
Novo Nordisk is committed to developing its business towards ecological, social and economic sustainability. This commitment is demonstrated through its values and its environmental and social responsibility policies.
Stock exchange listings
Novo Nordisk’s B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’.